Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Supreme Court Rejects J&J’s Appeal of Risperdal Penalty

By Drug Discovery Trends Editor | January 12, 2016

The U.S. Supreme Court on Monday declined to hear an appeal from Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, of a $124 million penalty imposed by South Carolina after a jury found the drugmaker had inappropriately marketed the antipsychotic medication risperidone (Risperdal) and covered up its risks.

Since the court decided not to hear J&J’s appeal, the South Carolina court ruling from June that reduced the penalty to $124 million from $327 million still stands, reports Reuters. J&J’s Janssen unit has been the South Carolina’s court win since 2011.

J&J lawyers cited the Eighth Amendment in arguing against the penalty, saying it violated the prohibiting of “excessive fines.”

In reducing the amount of the penalty the Supreme Court referred to a South Carolina law provision that states that no action can be taken in a case like this after three years of the discovery of unlawful conduct. South Carolina its complaint in April 2007.

The lawsuit centered on promotional materials J&J used to market Risperdal, in which the jury found that the company overstated Risperdal’s benefits compared with other similar drugs, and downplayed its side effects.

This is not the first lawsuit J&J has faced over its antipsychotic medication, Risperdal. In February, a jury in Philadelphia decided that J&J pay $2.5 million in damages for failing to warn that Risperdal could cause gynecomastia, or breast development, in males. That was the first lawsuit to go to trial over Risperdal’s ability to trigger gynecomastia, and J&J currently faces more than 1,000 lawsuits in similar cases, reports FiercePharma.

Risperdal, launched in 1994, treats schizophrenia, bipolar disorder and irritability in people with autism. Side effects associated with the drug include stroke, diabetes and weight gain.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE